• In late June 2026, Stryker Corporation (NYSE: SYK) was removed from several major Russell growth indexes, including the Russell 1000 Growth, Russell Top 200 Growth, and Russell 3000 Growth benchmarks, reshaping its presence in key passive investment universes.
• This broad index removal highlights how mechanical index rebalancing can rapidly alter who owns Stryker’s shares and how its stock trades, without changing the underlying business fundamentals.
• Next, we’ll examine how Stryker’s removal from multiple Russell growth indexes could influence its investment narrative and future investor expectations.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Stryker Investment Narrative Recap

To own Stryker, you have to believe in long term demand for its medical technology, from joint replacements to robotics and digital hospital solutions, and the company’s ability to execute through regulatory and cost pressures. The recent removal from several Russell growth indexes appears more about how the stock trades than what the business does, so it likely does not change the key near term catalyst of product approvals or the main risks around regulation and supply chain.

The upcoming Q2 2026 earnings webcast on July 30 is the most relevant announcement in this context, because it will give investors fresh detail on how Stryker is managing ongoing supply chain issues and higher input costs after the index related selling. That update should help frame whether recent volatility around valuation and ownership shifts squares with the company’s progress on its innovation pipeline and international expansion plans.

Yet beneath the index headlines, investors should be aware of the less visible risk that prolonged EU MDR approvals could...

Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029. This requires 8.9% yearly revenue growth and a $3.2 billion earnings increase from $3.3 billion today.

Uncover how Stryker's forecasts yield a $386.80 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community cluster between US$340 and US$400 per share, showing how widely individual views can differ. Against this, the risk of prolonged and unpredictable EU MDR approvals could have very real implications for Stryker’s future product rollouts and growth, so it is worth weighing several alternative viewpoints.

Explore 6 other fair value estimates on Stryker - why the stock might be worth just $340.49!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Stryker research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stryker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stryker's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.